Jean Pineault
Vorstandsvorsitzender bei Biohybrid Solutions Holding, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Krzysztof Matyjaszewski | M | - |
Biohybrid Solutions Holding, Inc.
 Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | - |
| Alan Russell | M | - |
Biohybrid Solutions Holding, Inc.
Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | 8 Jahre |
| Antonina Simakova | M | - |
Biohybrid Solutions Holding, Inc.
Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | 8 Jahre |
| Mark Murcko | M | 64 |
Biohybrid Solutions Holding, Inc.
Biohybrid Solutions Holding, Inc. BiotechnologyHealth Technology Biohybrid Solutions Holding, Inc. is a company that focuses on delivering safe and effective biologic drugs to patients worldwide. The company has partnered with the US government on a $38m DTRA program, which includes the discovery, manufacturing, testing, and scale-up of nanoarmored™ drugs. The company is based in Sharpsburg, PA. The company's world-renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: how to create longer-lived, more effective medicine. The company has developed the immunocontrol ™ platform, which can be used for epitopetargeting ™ and epitopeaccentuation ™, allowing for the discovery of new drugs against secondary, silent epitopes. The company has also modified cancer-fighting mini-proteins to increase pharmacokinetics. Biohybrid Solutions Holding was founded in 2016 by Antonina Simakova, Alan Russell, and Krzysztof Matyjaszewski. Jean Pineault has been the CEO of the company since 2021. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jacques Lemieux | M | - |
University of Ottawa
| 3 Jahre |
| Christophe J. Echeverri | M | - |
University of Ottawa
| 6 Jahre |
| Christopher C. Miller | M | - |
University of Ottawa
| 4 Jahre |
| Mei Jie Zhang | M | 60 |
University of Ottawa
| 3 Jahre |
| Samir Khan | M | - |
University of Ottawa
| 4 Jahre |
| Mike Morency | M | - |
University of Ottawa
| 3 Jahre |
| Karim Lalani | M | 58 |
University of Ottawa
| 3 Jahre |
| Jean-Michel Lemieux | M | - |
University of Ottawa
| 4 Jahre |
| Andrew Chuk | M | 66 |
University of Ottawa
| 3 Jahre |
| Robert Andre Seguin | M | - |
University of Ottawa
| 4 Jahre |
| Martin Bélanger | M | - |
University of Ottawa
| 4 Jahre |
| Duane William Green | M | - |
University of Ottawa
| 3 Jahre |
| Eric Paul-Hus | M | - |
University of Ottawa
| 3 Jahre |
| Stephen Partridge | M | - |
University of Ottawa
| 6 Jahre |
| Loon Chun Yang | M | 77 |
University of Ottawa
| 3 Jahre |
| Meena Ballantyne | F | - |
University of Ottawa
| 1 Jahre |
| Denis Zaccarin | M | 59 |
University of Ottawa
| 3 Jahre |
| Diane Lafontaine | F | - |
University of Ottawa
| 2 Jahre |
| Terrence Connolly | M | - |
University of Ottawa
| 5 Jahre |
| Raj Kumar | M | 55 |
University of Ottawa
| 4 Jahre |
| David Roy | M | - |
University of Ottawa
| 4 Jahre |
| Pik Sing Choi | M | - |
University of Ottawa
| 4 Jahre |
| Marco Bastidas | M | 59 |
University of Ottawa
| 4 Jahre |
| Ken Klassen | M | 58 |
University of Ottawa
| 3 Jahre |
| Peter Holst | M | 56 |
University of Ottawa
| 4 Jahre |
| Mark Deriet | M | - |
University of Ottawa
| 4 Jahre |
| Vincent Lépine | M | - |
University of Ottawa
| 1 Jahre |
| Doug Reid | M | - |
University of Ottawa
| 4 Jahre |
| Walter Spracklin | M | - |
University of Ottawa
| 4 Jahre |
| Marc Tellier | M | 55 |
University of Ottawa
| 4 Jahre |
| Scott Wilson | M | - |
University of Ottawa
| 4 Jahre |
| Elizabeth Douville | M | - |
University of Ottawa
| 3 Jahre |
| Perry Dellelce | M | - |
University of Ottawa
| 3 Jahre |
| Terry Connolly | F | - |
University of Ottawa
| 5 Jahre |
| Carl Pelland | M | - |
University of Ottawa
| 4 Jahre |
| James Lavigne | M | 60 |
University of Ottawa
| 1 Jahre |
| Richard Jonathan Fortin | M | - |
University of Ottawa
| 4 Jahre |
| Carlos Manuel Yuste | M | - |
University of Ottawa
| 4 Jahre |
| Francisco Diaz-Mitoma | M | 69 |
University of Ottawa
| 21 Jahre |
| Geneviève Lavallée | F | - |
University of Ottawa
| 5 Jahre |
| Irvine R. Annesley | M | - |
University of Ottawa
| 3 Jahre |
| Prashant R. Watchmaker | M | - |
University of Ottawa
| 4 Jahre |
| Paul N. Hughes | M | - |
University of Ottawa
| 4 Jahre |
| Bobbi Faulkner | F | - |
University of Ottawa
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Kanada | 44 | 91,67% |
| Vereinigte Staaten | 4 | 8,33% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jean Pineault
- Persönliches Netzwerk
